Experimental drug shown to slow multiple sclerosis disability

Experimental drug shown to slow multiple sclerosis disability

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests.

Experimental Drug Can Slow MS Disability

Key Takeaways

Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

Trial is the first to show a delay in confirmed disability progression in non-relapsing secondary progressive MS

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

The studies on the myelin of the central nervous system carried out by the Group of Neurobiology of Development-GNDe of the CSIC Cajal Institute work on a revolutionary therapy that consists of "incorporating remyelinizing drugs into the therapeutic arsenal of multiple sclerosis", explains researcher Fernando de Castro Soubriet who founded this group in 2003. The scientist talks about these advances in the investigation of multiple sclerosis thi…

Quantum BioPharma Expands Reach With New unbuzzd Launch and Cutting-Edge MS Clinical Study

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) is making headlines in April, launching its innovative alcohol detox drink, unbuzzd, in Puerto Rico and initiating a groundbreaking clinical study aimed at revolutionizing the diagnosis and treatment monitoring of multiple sclerosis (MS). Revolutionary Beverage Hits Puerto Rico Celly Nutrition, a licensee of Quantum BioPharma, introduced unbuzzd, a beverage designed to rapidly metabolize a…